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Abstract
Objective: The study was performed to investigate the association of  interleukin 17 (IL 17) or angiotensin II (Ang II) with 
refractory hypertension risk in hemodialysis patients.
Methods: Ninety hemodialysis patients were enrolled into this study, and those with hypertension were divided into two groups. 
The Easy-to-Control Hypertension group (ECHG) had fifty patients, while the refractory hypertension group (RHG) had forty 
patients. Twenty healthy individuals were recruited as the control group. IL17 and Ang II were determined using a human IL 17 
/ Ang II enzyme-linked immunosorbent assay kit. Serum IL 17 and Ang II concentrations in RHG patients were higher than 
those in ECHG patients. 
Results: Serum IL 17 and Ang II concentrations in both patient groups were higher than those in the control group. Linear 
regression analysis showed  a positive correlation between IL 17 and Ang II. In multivariate regression analysis, we  found  that 
IL17 and Ang II were associated with refractory hypertension risk in hemodialysis patients.
Conclusion: IL17 and Ang II were associated with refractory hypertension risk in hemodialysis patients. There was also a posi-
tive correlation between IL 17and Ang II.
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Introduction
Patients with End State Renal Disease (ESRD) present 
very late and with cardiovascular complications1. Fur-
thermore, patients with ESRD who are going for dialy-
sis tend to have refractory hypertension, anemia, and 
other complications2,3. Many ESRD patients have to 
take several kinds of  anti-hypertensive drugs, but even 
when they receive the maximum permissible doses; it 
remains difficult to treat their hypertension. Currently, 
about 70% of  hemodialysis patients fail to have their 
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hypertension controlled2, and there is increased mortal-
ity and cardiovascular and cerebrovascular morbidity 
among them4. Activation of  the Renin-Angiotensin-Al-
dosterone System (RAAS) and hypervolaemia are often 
found and considered to be the main causes of  refrac-
tory hypertension in Chronic Kidney Disease (CKD) 
patients5,6. However, blocking the RAAS, and control-
ling the volume of  blood are not good approaches to 
treating the refractory hypertension well. Angiotensin 
II (Ang II) is the major effect messenger of  the RAAS 
and exhibits a wide range of  responses, for instance in-
duction of  the accumulation and deposition of  colla-
gen7.                                                                                                                                                                                            
Interleukin 17 (IL 17), with a molecular weight of  35kDa, 
is a type of  homodimeric glycoprotein containing 155 
amino acids and is generated by Th17 cells8. IL 17 is a 
critical factor in assisting mammals to defend against a 
wide range of  pathogens8,9. Angiotensin II (Ang II) can 
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stimulate Th17 cells to generate IL17. Madhur et al10 dis-
covered that IL17 is important in the development of  
hypertension. Serum IL 17 level in hypertension patients 
is much higher than that in normal individuals, and IL 17 
concentration is positively correlated with blood pressure 
values. Interestingly, Chung et al11 found that hemodialysis 
patients had an evidently increased IL 17 level, compared 
to healthy people in the control group, and IL17 could 
not be removed from the body by hemodialysis. There-
fore, IL 17 could play a role in the causation of  refractory 
hypertension in hemodialysis. This study was performed 
to assess the association between IL 17, angiotensin II 
and refractory hypertension risk in hemodialysis patients.
 
Methods
This study was performed in the Department of  Ne-
phrology, the Second Affiliated Hospital of  GuangZhou 
Medical University, GuangZhou, China. From December 
2012 to December 2014, 90 hemodialysis patients were 
enrolled into the study, and they were newly treated with 
steady hemodialysis for at least three months. Exclusion 
criteria included the presence of  inflammatory disease, 
malignancy, chronic liver disease, chronic obstructive air-
way disease, chronic rheumatic heart disease, congenital 
heart disease, and those patients aged below 18 years or 
above 70.
The causes of  ESRD included chronic glomerulonephri-
tis in 35 patients, diabetic nephropathy in 27 patients, 
hypertensive nephrosclerosis in 20 patients, obstructive 
uropathy in 3 patients, tubulointerstitial nephritis in 3 pa-
tients, and unknown etiology in 2 patients. Fifty patients 
were put into the easy-to-control hypertension group 
(ECPG), while forty others were put into the refractory 
hypertension group (RHG). Twenty healthy individuals 
were used as the control group in order to define basal 
IL 17 level. The study was approved by the University 
ethics committee, and written informed consent was ob-
tained from all patients and healthy individuals before 
they joined the study.
Supine blood pressure (BP) was measured three times 
with a mercury sphygmomanometer, and the first and 
fifth Korotokoff  sounds were taken as systolic and di-
astolic. Mean arterial pressure (MAP) was calculated as 
diastolic BP+1/3 (systolic BP-diastolic BP). Patients’ 
systolic BP<140mmHg and diastolic BP<90mmHg were 
considered to have attained the goal of  anti-hypertension 
treatment. Refractory hypertension was defined as blood 
pressure that was above the goal in spite of  the concur-
rent use of  three antihypertensive agents given in appro-
priate doses of  different classes for at least three months 
12.
The blood samples were drawn before dialysis. Fast-
ing venous blood was collected for the measurement 
of  high sensitivity CRP (hs-CRP), serum albumin, cal-
cium, phosphorus, Parathyroid hormone (PTH), choles-
terol (CHOL), triglycercide (TG), low-density lipoprotein 
(LDL), and high-density lipoprotein (HDL). IL 17 and 
Ang II were determined using human Enzyme-Linked 
Immunosorbent Assay (ELISA) kits (Shanghai Lengton 
Bioscience Co., Shanghai, China). All specimens were 
measured in triplicate.
Total weekly urea clearance (Kt/V) was measured to 
assess the adequacy of  dialysis. ACE inhibitor, ARB, 
β-blocker, calcium channel clocker, or α-blocker were 
used to control the patients’ hypertension, and all hemo-
dialysis patients received two or more antihypertensive 
drugs including ACE inhibitor or ARB.
 
Statistical analysis
Data was expressed as means ± SD (standard deviation). 
Baseline characteristics of  hemodialysis patients in the 
two groups were compared using Analysis Of  Variance 
(ANOVA) for continuous data and chi-square analyses 
for categorical data. Comparisons of  the IL 17 expres-
sion among the control, ECHG, and RHG group, were 
performed using one-way ANOVA for continuous vari-
ables and X2 statistics for differences in proportion. Mul-
tivariate regression analyses were done to evaluate the re-
lationships between IL 17, Ang II and blood pressure. A 
p value﹤0.05 was considered statistically significant.
 
Results
Baseline characteristics of  patients in the two hemo-
dialysis patients groups
Baseline characteristics of  the ECHG group and RHG 
group are shown in Table 1. The average age was 
55.30±9.25 years in the ECHG group and 54.47±9.26 
years in the RHG group. The ratio of  males to females 
was 26:24 and 24:16 in the ECHG and RHG group re-
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spectively. There was no difference in the incidence of  
diabetes, hemoglobin, albumin, hsCPR, calcium, phos-
phorus, and lipoprotein between the two groups. IL 17 
and Ang II concentrations were 10.88±1.41 pg/m land 
89.09±24.03 ng/L in the ECHG group; and 14.51±1.43 
pg/ml and 118.02±12.21 ng/L in the RHG group. There 
was difference between two groups (p<0.01, Table 1).
Table 1. Clinical characteristics of patients between ECHG group and RHG group 
  
  ECHG RHG P value 
Age（year） 55.30±9.25 54.47±9.26 0.676 
Male/female 26/24 24/16 0.450 
Diabetes incidence 12 10 0.913 
Systolic pressure 120.18±15.07 159.37±18.05 0.000 
Diastolic pressure 73.00±10.79 98.05±9.96 0.000 
Mean arterial pressure (MAP) 88.72±12.07 118.49±11.30 0.000 
BMI（kg/m2） 23.10±3.61 23.59±3.63 0.524 
Hb(g/L) 116.10±22.15 111.30±20.44 0.421 
ALB(g/L) 36.02±5.17 35.88±5.45 0.901 
hsCRP(mg/L) 3.50(0.87, 8.9) 3.52(0.87, 8.85) 0.803 
iPTH(pg/L) 30.56±50.41 33.34±55.88 0.809 
Ca（mmol/L） 2.29±0.28 2.30±0.28 0.903 
P（mmol/L） 1.55±0.42 1.57±0.43 0.788 
TC（mmol/L） 4.77±1.12 4.67±1.09 0.672 
TG（mmol/L） 3.34±8.17 3.50±9.11 0.930 
HDL（mmol/L） 0.98±0.25 0.98±0.26 0.960 
LDL（mmol/L） 2.46±0.78 2.55±0.79 0.565 
IL 17(pg/ml) 10.88±1.41 14.51±1.43 0.000 
Angiotensin II(ng/L) 89.09±24.03 118.02±12.21 0.000 
eGFR（ml/min） 9.63±3.73 9.54±3.95 0.912 
Kt/v 1.3±0.12 1.3±0.04 0.860 
      Notes: ECHG: easy-to-control hypertension group; RHG: refractory hypertension 
group; BMI: body mass index; eGFR: estimated glomerular filtration rate 
The relationships between IL17, Ang II, and MAP
Linear regression analysis showed a positive linear cor-
relation between IL 17 and Ang II, with a regression 
coefficient (B) of  7.617(95%CI 6.969-8.264), t=23.375, 
p﹤0.01, R2=0.861 (Fig 1 A).
IL 17 and MAP also had a positive linear correlation, 
with a regression coefficient (B) of  0.081 (95%CI 0.071-
0.092), t=15.709, p﹤0.01, R2=0.737 (Fig 1 B).
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In the multiple linear regression analysis for MAP, serum 








 Fig 1. Linear regression analysis showed linear correlation between angiotensin II , IL 17 and MAP. A. 
Linear regression analysis showed positive linear correlation between angiotensin II and IL 17, the 
regression coefficient(B) was 7.617(95%CI 6.969-8.264), t=23.375, p＜0.01, R2=0.861. B. Linear regression 
analysis showed positive linear correlation between IL 17 and MPA, the regression co-efficient(B) was 








 Fig 1. Linear regression analysis showed linear correlation between angiotensin II , IL 17 and MAP. A. 
Linear regression analysis showed positiv  li ear correlation between angiote sin II and IL 17, the 
regression coefficient(B) was 7.617(95%CI 6.969-8.264), t=23.375, p＜0.01, R2=0.861. B. Lin ar regression 
analysis showed po itiv  linear correlation between IL 17 and MPA, the regression co-efficient(B) was 
0.081(95%CI 0.071-0.092), t=15.709, p＜0.01, R2=0.737. 
t=2.442, P=0.017) had significant correlation with MAP 
after adjusting for age, diabetes, BMI, hemoglobin, 
hsCRP, eGFR, and Kt/v.
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Table 2 Multiple linear regression analysis showing relationship between IL 17, Ang II 
and mean arterial pressure in hemodialysis patients. 
 
Variables B t value P value 
IL 17 6.320 10.221 0.000 
Ang II 0.143 2.442 0.017 
  
Discussion
This study aimed to investigate the association between 
IL 17 and the risk of  refractory hypertension in hemodi-
alysis patients. We found that  increased IL 17 was associ-
ated with the risk of  refractory hypertension in hemodi-
alysis patients. We did not find any other study reporting 
this relationship. However, our study had a small sample 
size. More studies with larger sample sizes could be per-
formed to confirm these findings.
 
Interestingly, we also found that the increased Ang II was 
associated with the risk of  refractory hypertension in he-
modialysis patients. A number of  previous studies report 
that the increased Ang II was associated with the hyper-
tension, and ACE inhibitor, ARB could reduce the value 
of  BP13-15. In this study, we reported a positive correla-
tion between Ang II and IL 17. However, the mechanism 
should be assessed more in the future.
The most common finding in dialysis patients with re-
fractory hypertension is volume overload. In this study, 
the volume overload was controlled for all the patients. 
However, since it was an observational study, we could 
not answer this question that dialysis patients with refrac-
tory hypertension have  volume overload.
In conclusion, we found  that IL17 and Ang II were as-
sociated with refractory hypertension risk in hemodialysis 
patients, and there was a positive correlation between IL 
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